Table 2.
Clinical Features of Included Studies
| Study | Cohort Size, No. | Previous Debulking, No., % | Previous Radiation, No., % | Previous Chemotherapy, No., % | Bevacizumab Regimen (Median No. of Doses) | Other Agents | Clinical Responses | Serious Adverse Events With Bevacizumab | Progression, No., % |
|---|---|---|---|---|---|---|---|---|---|
| Zhukova et al, 201923 | 15 | 1, 7% | 1, 7% | 15, 100% | 10 mg/kg every 2 wks (16) | Multiplea | 4 improved vison, 2 improved motor, 1 improved endocrine | 2 proteinuria | 5, 33% |
| Gorsi et al, 201819 | 15 | 0 | 4, 27% | 12, 80% | 10 mg/kg every 2 wks (10) | No | 7 improved motor, 4 improved vision | 1 bone pain, 1 hyperglycemia, 1 hyperkalemia | 11, 73% |
| Kalra et al, 201522 | 16 | 11, 70% | 3, 19% | 16, 100% | 10 mg/kg every 2 wks (24) | Irinotecan | 3 improved headache, 2 improved vision, 2 improved motor | 2 nauseab | 4, 25% |
| Hsu et al, 201521 | 8 | 0 | 0 | 6, 75% | 10 mg/kg every 2 wks (16) | No | NR | 0 | NR |
| Gururangan et al, 201420 | 35 | 0 | 2, 6% | 35, 100% | 10 mg/kg every 2 wks (12) | Irinotecan | NR | 3 proteinuria, 4 neutropeniab, 2 diarrheab | 20, 57% |
| Hwang et al, 201213 | 14 | 4, 30% | 3, 21% | 13, 93% | 10 mg/kg every 2 wks (24) | Irinotecan | 4 improved vision, 4 improved endocrine, 2 improved ataxia, 1 improvement motor | 1 proteinuria, 1 fatigue, 1 gastrointestinal, 1 synovitis | 13, 93% |
| Couec et al, 201218 | 7 | NR | NR | NR | 10 mg/kg every 2 wks (16) | Irinotecan | NR | 0 | 1, 14% |
Abbreviation: NR, not reported.
aIrinotecan, carboplatin, vinblastine, vincrinstine, and lomustine.
bIrinotecan-associated event.